All In Biotech

Drug Trial Radar · NCT03989414

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

424

Planned (sponsor's estimate)

Start

Sep 30, 2019

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jun 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Conditions

  • Multiple Myeloma

Interventions

  • CC-92480Drug

    Specified dose on specified days

  • BortezomibDrug

    Specified dose on specified days

  • DexamethasoneDrug

    Specified dose on specified days

  • DaratumumabDrug

    Specified dose on specified days

  • CarfilzomibDrug

    Specified dose on specified days

  • ElotuzumabDrug

    Specified dose on specified days

  • IsatuximabDrug

    Specified dose on specified days

  • CarfilzomibDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended DoseTime frame: Up to approximately 3 years
  2. Recommended regimen as measured by dose-limiting toxicitiesTime frame: Up to approximately 3 years
  3. Number of participants with Adverse Events (AEs)Time frame: From first participant first visit until 28 days after the last subject discontinues study treatment, up to 5 years
  4. Overall response rate (ORR)Time frame: Up to approximately 5 years

Locations

49 sites in 9 countries. Site status is shown where the registry gives one.

  • Local Institution - 119

    Denver, Colorado

  • Local Institution - 104

    Tampa, Florida

  • Local Institution - 108

    Atlanta, Georgia

  • Local Institution - 112

    Chicago, Illinois

  • Local Institution - 107

    Chicago, Illinois

  • Local Institution - 117

    Boston, Massachusetts

  • Local Institution - 101

    Boston, Massachusetts

  • Local Institution - 118

    Boston, Massachusetts

  • Local Institution - 113

    Detroit, Michigan

  • Local Institution - 106

    Rochester, Minnesota

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Local Institution - 110

    Winston-Salem, North Carolina

  • Local Institution - 115

    Columbus, Ohio

  • Local Institution - 114

    Nashville, Tennessee

  • Local Institution - 116

    Houston, Texas

  • Swedish Cancer Institute

    Seattle, Washington

  • Local Institution - 201

    Calgary, Alberta, Canada

  • Local Institution - 205

    Edmonton, Alberta, Canada

  • Local Institution - 204

    Halifax, Nova Scotia, Canada

  • Local Institution - 203

    Toronto, Ontario, Canada

  • Local Institution - 202

    Montreal, Quebec, Canada

  • Local Institution - 802

    Brno, Czechia

  • Local Institution - 801

    Ostrava-Poruba, Czechia

  • Local Institution - 803

    Prague, Czechia

  • Local Institution - 902

    Odense, Denmark

  • Local Institution - 903

    Vejle, Denmark

  • Local Institution - 703

    Lille, France

  • Local Institution - 705

    Marseille, France

  • Local Institution - 704

    Nantes, France

  • Local Institution - 701

    Toulouse, France

  • Local Institution - 702

    Tours, France

  • Local Institution - 604

    Freiburg im Breisgau, Germany

  • Local Institution - 605

    Hamburg, Germany

  • Local Institution - 601

    Heidelberg, Germany

  • Local Institution - 602

    München, Germany

  • Local Institution - 603

    Würzburg, Germany

  • Local Institution - 301

    Athens, Greece

  • Local Institution - 404

    Brescia, Italy

  • Local Institution - 401

    Milan, Italy

  • Local Institution - 403

    Reggio Emilia, Italy

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.